Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway

Ilana Chefetz; Jennie C. Holmberg; Ayesha B. Alvero; Irene Visintin; Gil Mor

doi:10.4161/cc.10.13.16348

Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway

Ilana Chefetz, Jennie C. Holmberg, Ayesha B. Alvero, Irene Visintin, Gil Mor

Hormel Institute

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Abstract

Recurrent ovarian cancer is resistant to conventional chemotherapy. A sub-population of ovarian cancer cells, the epithelial ovarian cancer stem cells (EOC stem cells) have stemness properties, constitutive NFκB activity, and represent the chemoresistant population. Currently, there is no effective treatment that targets these cells. Aurora-A kinase (Aurora-A) is associated with tumor initiation and progression and is overexpressed in numerous malignancies. The aim of this study is to determine the effect of Aurora-A inhibition in EOC stem cells. EOC stem cells were treated with the Aurora-A inhibitor, MK-5108. Cell growth was monitored by Incucyte real-time imaging system, cell viability was measured using the Celltiter 96 assay and cytokine levels were quantified using xMAP technology. The intracellular changes associated with MK-5108 treatment are: (1) polyploidy and cell cycle arrest; (2) inhibition of NFκB activity; (3) decreased cytokine production; and (4) nuclear accumulation of IκBα. Thus, inhibition of Aurora-A decreases cell proliferation in the EOC stem cells by inducing cell cycle arrest and affecting the NFκB pathway. As EOC stem cells represent a source of recurrence and chemoresistance, these results suggest that Aurora-A inhibition may effectively target the cancer stem cell population in ovarian cancer.

Original language	English (US)
Pages (from-to)	2206-2214
Number of pages	9
Journal	Cell Cycle
Volume	10
Issue number	13
DOIs	https://doi.org/10.4161/cc.10.13.16348
State	Published - Jul 1 2011

Bibliographical note

Funding Information:
two κB sites before a FOS essential promoter (a gift from Dr. S. This study was supported in part by Merck and grants from Ghosh, Yale University). Cells were stably transfected and lucif-NCI/NIH RO1CA127913, RO1CA118678, The Janet Burros erase activity measured as previously described in reference 10. Memorial Foundation, The Sands Family Foundation, The Cytokine profiling. Levels of cytokines and chemokines Brozman Foundation and the Discovery To Cure Research were measured from cell-free supernatants using the Bioplex Program. I.C. is Life Science Research Foundation Postdoctoral Pro Cytokine Assay (Biorad, Hercules, CA). Data were acquired Fellow.

Keywords

Aurora-A kinase
Cell cycle arrest
Nuclear factor kappaB
Ovarian cancer stem cells

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.4161/cc.10.13.16348

OpenUrl availability

Full text

Cite this

@article{03f09295ff6e43e4810162420ce1d8fc,

title = "Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway",

abstract = "Recurrent ovarian cancer is resistant to conventional chemotherapy. A sub-population of ovarian cancer cells, the epithelial ovarian cancer stem cells (EOC stem cells) have stemness properties, constitutive NFκB activity, and represent the chemoresistant population. Currently, there is no effective treatment that targets these cells. Aurora-A kinase (Aurora-A) is associated with tumor initiation and progression and is overexpressed in numerous malignancies. The aim of this study is to determine the effect of Aurora-A inhibition in EOC stem cells. EOC stem cells were treated with the Aurora-A inhibitor, MK-5108. Cell growth was monitored by Incucyte real-time imaging system, cell viability was measured using the Celltiter 96 assay and cytokine levels were quantified using xMAP technology. The intracellular changes associated with MK-5108 treatment are: (1) polyploidy and cell cycle arrest; (2) inhibition of NFκB activity; (3) decreased cytokine production; and (4) nuclear accumulation of IκBα. Thus, inhibition of Aurora-A decreases cell proliferation in the EOC stem cells by inducing cell cycle arrest and affecting the NFκB pathway. As EOC stem cells represent a source of recurrence and chemoresistance, these results suggest that Aurora-A inhibition may effectively target the cancer stem cell population in ovarian cancer.",

keywords = "Aurora-A kinase, Cell cycle arrest, Nuclear factor kappaB, Ovarian cancer stem cells",

author = "Ilana Chefetz and Holmberg, {Jennie C.} and Alvero, {Ayesha B.} and Irene Visintin and Gil Mor",

note = "Funding Information: two κB sites before a FOS essential promoter (a gift from Dr. S. This study was supported in part by Merck and grants from Ghosh, Yale University). Cells were stably transfected and lucif-NCI/NIH RO1CA127913, RO1CA118678, The Janet Burros erase activity measured as previously described in reference 10. Memorial Foundation, The Sands Family Foundation, The Cytokine profiling. Levels of cytokines and chemokines Brozman Foundation and the Discovery To Cure Research were measured from cell-free supernatants using the Bioplex Program. I.C. is Life Science Research Foundation Postdoctoral Pro Cytokine Assay (Biorad, Hercules, CA). Data were acquired Fellow.",

year = "2011",

month = jul,

day = "1",

doi = "10.4161/cc.10.13.16348",

language = "English (US)",

volume = "10",

pages = "2206--2214",

journal = "Cell Cycle",

issn = "1538-4101",

publisher = "Landes Bioscience",

number = "13",

}

TY - JOUR

T1 - Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway

AU - Chefetz, Ilana

AU - Holmberg, Jennie C.

AU - Alvero, Ayesha B.

AU - Visintin, Irene

AU - Mor, Gil

N1 - Funding Information: two κB sites before a FOS essential promoter (a gift from Dr. S. This study was supported in part by Merck and grants from Ghosh, Yale University). Cells were stably transfected and lucif-NCI/NIH RO1CA127913, RO1CA118678, The Janet Burros erase activity measured as previously described in reference 10. Memorial Foundation, The Sands Family Foundation, The Cytokine profiling. Levels of cytokines and chemokines Brozman Foundation and the Discovery To Cure Research were measured from cell-free supernatants using the Bioplex Program. I.C. is Life Science Research Foundation Postdoctoral Pro Cytokine Assay (Biorad, Hercules, CA). Data were acquired Fellow.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Recurrent ovarian cancer is resistant to conventional chemotherapy. A sub-population of ovarian cancer cells, the epithelial ovarian cancer stem cells (EOC stem cells) have stemness properties, constitutive NFκB activity, and represent the chemoresistant population. Currently, there is no effective treatment that targets these cells. Aurora-A kinase (Aurora-A) is associated with tumor initiation and progression and is overexpressed in numerous malignancies. The aim of this study is to determine the effect of Aurora-A inhibition in EOC stem cells. EOC stem cells were treated with the Aurora-A inhibitor, MK-5108. Cell growth was monitored by Incucyte real-time imaging system, cell viability was measured using the Celltiter 96 assay and cytokine levels were quantified using xMAP technology. The intracellular changes associated with MK-5108 treatment are: (1) polyploidy and cell cycle arrest; (2) inhibition of NFκB activity; (3) decreased cytokine production; and (4) nuclear accumulation of IκBα. Thus, inhibition of Aurora-A decreases cell proliferation in the EOC stem cells by inducing cell cycle arrest and affecting the NFκB pathway. As EOC stem cells represent a source of recurrence and chemoresistance, these results suggest that Aurora-A inhibition may effectively target the cancer stem cell population in ovarian cancer.

AB - Recurrent ovarian cancer is resistant to conventional chemotherapy. A sub-population of ovarian cancer cells, the epithelial ovarian cancer stem cells (EOC stem cells) have stemness properties, constitutive NFκB activity, and represent the chemoresistant population. Currently, there is no effective treatment that targets these cells. Aurora-A kinase (Aurora-A) is associated with tumor initiation and progression and is overexpressed in numerous malignancies. The aim of this study is to determine the effect of Aurora-A inhibition in EOC stem cells. EOC stem cells were treated with the Aurora-A inhibitor, MK-5108. Cell growth was monitored by Incucyte real-time imaging system, cell viability was measured using the Celltiter 96 assay and cytokine levels were quantified using xMAP technology. The intracellular changes associated with MK-5108 treatment are: (1) polyploidy and cell cycle arrest; (2) inhibition of NFκB activity; (3) decreased cytokine production; and (4) nuclear accumulation of IκBα. Thus, inhibition of Aurora-A decreases cell proliferation in the EOC stem cells by inducing cell cycle arrest and affecting the NFκB pathway. As EOC stem cells represent a source of recurrence and chemoresistance, these results suggest that Aurora-A inhibition may effectively target the cancer stem cell population in ovarian cancer.

KW - Aurora-A kinase

KW - Cell cycle arrest

KW - Nuclear factor kappaB

KW - Ovarian cancer stem cells

UR - http://www.scopus.com/inward/record.url?scp=79960012417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960012417&partnerID=8YFLogxK

U2 - 10.4161/cc.10.13.16348

DO - 10.4161/cc.10.13.16348

M3 - Article

C2 - 21623171

AN - SCOPUS:79960012417

SN - 1538-4101

VL - 10

SP - 2206

EP - 2214

JO - Cell Cycle

JF - Cell Cycle

IS - 13

ER -

Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this